Eprenetapopt was also studied with AZA in the post-HSCT maintenance setting in TP53-mutant AML and MDS in a phase II trial (NCT03931291) with a median OS of 20.6 months [113]. This evidence concerns the gene TP53 and myelodysplastic syndrome.